With the expansion of SGLT-2 inhibitor coverage, which began in April, combination prescriptions of various diabetes drugs and SGLT-2 drugs are expected to increase. However, as the clinical basis for each drug is a prerequisite for the expansion of this benefit, there are differences in detailed application depending on the presence or absence of clinical trials. Expectations are growing that AstraZeneca's Forxiga, which has the most clinical trials among SGLT-2 inhibitors, will rise further.

Kim Jong-Hwa, head of the Department of Endocrinology at Bucheon Sejong Hospital (insurance director of the Korean Diabetes Association), said, “Forxiga is the first SGLT-2 inhibitor in Korea and has the